BridgeBio Pharma, Inc. has announced the pricing of $500 million in convertible senior notes at a 1.75% interest rate, maturing in 2031, in a private offering aimed at qualified institutional buyers.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback